The potent oxidant anticancer activity of organoiridium catalysts by Liu, Z. et al.
 The University of Bradford Institutional 
Repository 
http://bradscholars.brad.ac.uk 
This work is made available online in accordance with publisher policies. Please refer to the 
repository record for this item and our Policy Document available from the repository home 
page for further information. 
To see the final version of this work please visit the publisher’s website. Access to the 
published online version may require a subscription. 
Link to publisher’s version: http://dx.doi.org/10.1002/anie.201311161 
Citation: Liu Z, Romero-Canelón I, Qamar B et al (2014) The potent oxidant anticancer activity of 
organoiridium catalysts. Angewandte Chemie International Edition. 53(15): 3941-3946.  
Copyright statement: ©2014 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. 
This is an open access article under the terms of the Creative Commons Attribution License, 
which permits use, distribution and reproduction in any medium, provided the original work is 
properly cited. 
 
Iridium Anticancer Drugs Very Important Paper
DOI: 10.1002/anie.201311161
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Abstract: Platinum complexes are the most widely used
anticancer drugs; however, new generations of agents are
needed. The organoiridium(III) complex [(h5-Cpxbiph)Ir-
(phpy)(Cl)] (1-Cl), which contains p-bonded biphenyltetra-
methylcyclopentadienyl (Cpxbiph) and C^N-chelated phenyl-
pyridine (phpy) ligands, undergoes rapid hydrolysis of the
chlorido ligand. In contrast, the pyridine complex [(h5-
Cpxbiph)Ir(phpy)(py)]+ (1-py) aquates slowly, and is more
potent (in nanomolar amounts) than both 1-Cl and cisplatin
towards a wide range of cancer cells. The pyridine ligand
protects 1-py from rapid reaction with intracellular gluta-
thione. The high potency of 1-py correlates with its ability to
increase substantially the level of reactive oxygen species
(ROS) in cancer cells. The unprecedented ability of these
iridium complexes to generate H2O2 by catalytic hydride
transfer from the coenzyme NADH to oxygen is demonstrated.
Such organoiridium complexes are promising as a new gen-
eration of anticancer drugs for effective oxidant therapy.
Three platinum-based anticancer drugs, cisplatin (CDDP),
carboplatin, and oxaliplatin (OXA), are involved in nearly
50% of all anticancer therapies worldwide; however, prob-
lems of platinum resistance and undesirable side effects are
limiting their future use.[1] This highlights the need to develop
anticancer agents with new mechanisms of action (MoAs). In
contrast to the DNA-targeting platinum drugs, some organo-
metallic complexes that seem to be promising[2] offer the
possibility of alternative redox MoAs. Oxidative stress caused
by the generation of reactive oxygen species (ROS) is an
effective method of killing cancer cells.[3] ROS are produced
in a wide range of physiological processes, in particular by
mitochondria, and play valuable roles in cellular signaling.
Uncontrolled and excessive production of ROS, or a dimin-
ished ability of cells to scavenge ROS, gives rise to oxidative
stress and subsequent damage to various cellular components.
As cancer cells are often under increased oxidative stress
compared to normal cells, which is partially due to abnormal
mitochondrial functions, an element of selectivity is achieved
when an anticancer agent further increases the level of
oxidative stress. Such stress would have a smaller effect on
redox control in normal cells.
Organometallic iridium(III) complexes are particularly
promising. Complexes of this third-row low-spin transition-
metal ion with a 5d6 electron configuration are often thought
to be inert. Indeed, [Ir(H2O)6]
3+ exchanges ligands on a time
scale of hundreds of years.[4] However, the introduction of
a cyclopentadienyl ligand can increase the ligand exchange
rate by 14 orders of magnitude.[5] There is current interest in
the design of both inert and labile IrIII complexes as
anticancer agents.[6] The activity of half-sandwich cyclopen-
tadienyl anticancer complexes [(h5-Cpx)IrIII(X^Y)Cl]0/+,
where Cpx can be a pentamethylcyclopentadienyl (Cp*),
phenyltetramethylcyclopentadienyl (Cpxph), or biphenyltetra-
methylcyclopentadienyl (Cpxbiph) moiety, and X^Y is a chelat-
ing ligand, is highly dependent both on the Cp* substituents
and on the X^Y ligand.[6a–c] These chlorido complexes all
hydrolyze rapidly (within minutes at 310 K), including [(h5-
Cpxbiph)Ir(phpy)Cl] (1-Cl ; phpy= 2-phenylpyridine), which is
one of the most potent complexes.[6c]
Herein, we show that the monodentate ligand can have
a major influence on both chemical reactivity and anticancer
potency. We compare the aquation of the chlorido complex 1-
Cl with that of the pyridine (py) complex [(h5-Cpxbiph)Ir-
(phpy)py]+ (1-py). We investigated their activity towards
a wide range of cancer cells and their selectivity for cancer
cells over normal cells and used COMPARE analysis to
explore the potential MoAs. We related cellular accumulation
of iridium and production of ROS in cells to the redox
chemistry of the complexes. In particular, we asked whether
the ability of the cyclopentadienyl IrIII complexes to accept
a hydride from the coenzyme NADH can be linked to ROS
production. We demonstrate that organometallic iridium
complexes can be used as highly effective, even catalytic,
oxidants for the treatment of cancer.
The novel compound 1-py·PF6 was synthesized from the
chlorido analogue 1-Cl, isolated as the PF6
 salt (Figure 1a),
and fully characterized by 1H and 13C NMR spectroscopy,
ESI-MS, CHN elemental analysis, HPLC (Figure S1), and X-
ray crystallography (Figure 1b; for details see the Supporting
Information, Tables S1 and S2).
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First, we assessed the anticancer activity of 1-py in
comparison with that of 1-Cl (and cisplatin) and probed
their MoAs. We then studied chemical reactions of 1-py that
might play a key role in determining its biological activity,
especially novel pathways for the production of ROS.
Complex 1-py showed high potency with an IC50 value
(the concentration at which 50% of cell growth is inhibited)
of 120 nm towards A2780 human ovarian cancer cells, which
renders it six times more active than 1-Cl,[6c] and approx-
imately ten times more active than cisplatin (Figure 2a and
Table S3). Moreover, 1-py is thirteen times less toxic towards
normal cells (MRC-5 human lung fibroblast cells) than
towards A2780 cancer cells, whereas 1-Cl has a much lower
selectivity factor of four (Figure 2a). Interestingly, the anti-
proliferative activity of 1-py towards A2780 cells after
exposure for four hours is the same as that after 24 hours,
which implies that the onset of cell death is a relatively rapid
process (Figure S2 and Table S4).
The antiproliferative activities of 1-Cl[7] and 1-py were
further evaluated by the National Cancer Institute NCI-60
human cancer cell screen,[8] which consists of nine tumor
subtypes and approximately 60 cell lines (Figure 2c and
Figure S3). Three endpoints were determined: the GI50 (the
concentration that causes 50% cell growth inhibition), TGI
(concentration that causes 100% cell growth inhibition), and
LC50 values (the concentration that decreases the original cell
count by 50%). Complex 1-py is six (GI50) to thirteen (LC50)
times more potent than CDDP and approximately three times
Figure 1. a) Synthesis route for 1-py·PF6. b) X-ray crystal structure of
[(h5-Cpxbiph)Ir(phpy)py]PF6·(CH3OH)0.5,; thermal ellipsoids set at 20%
probability. The H atoms, counterions, and solvent have been omitted
for clarity.
Figure 2. Antiproliferative activity. a) IC50 in A2780 cancer cells and MRC-5 normal lung fibroblasts of 1-py, 1-Cl,
[6c] and CDDP. b) GI50, TGI, and
LC50 values (mm) of 1-Cl,
[7] 1-py, and CDDP in the NCI-60 screen. c) Heat map for GI50 values of 1-Cl, 1-py, CDDP, and oxaliplatin (OXA). The deep
red color corresponds to the highest activity, whereas the deep blue color represents the lowest activity.
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more potent than 1-Cl (Figure 2b). Complex
1-py shows high potency towards a wide range
of cancer cell lines (Figure S3), with particular
selectivity towards colon, melanoma, and
non-small-cell lung cancer (NSCLC). Com-
plex 1-py displayed its highest potency
towards the MDA-MB-468 breast cell line
with a GI50 value of 132 nm. The high potency
of 1-py contrasts with the loss of activity when
a chloride in a RuII arene anticancer complex
[(h6-hexamethylbenzene)Ru(en)Cl]+ is sub-
stituted by pyridine.[9]
The heat map highlights the distinct
differences between the iridium compounds
and the platinum drugs (Figure 2c). Strik-
ingly, 1-py is more active in almost all of the
cell lines, and the pattern of selectivity is very
different for the iridium and platinum com-
plexes, suggesting different MoAs. We used
the NCI COMPARE algorithm, which quan-
titatively compares the selectivity in the NCI-
60 screen of a seed compound with a database
of compounds, to produce a Pearsons corre-
lation coefficient between 1 (negative cor-
relation) and +1 (positive correlation), as
a measure of similarity.[7,8] COMPARE anal-
ysis of 1-py showed no correlation to any
platinum compounds when we assessed the
top 100 correlations with the DTP/NIH
synthetics compound database, which hosts
more than 40000 pure, natural and synthetic
compounds. This result quantitatively suggests that the MoA
of 1-py is different from that of cisplatin and other platinum
compounds. In contrast, COMPARE analysis gave a correla-
tion coefficient of 0.744 for 1-py and 1-Cl across the NCI-60
panel, suggesting that they have similar MoAs.
We also investigated the accumulation of complexes 1-Cl
and 1-py in A2780 cells. After 24 hours of drug exposure, the
amount of iridium that had accumulated in the cells was
20 times larger when complex 1-py was used instead of 1-Cl
(8.3 0.3 ng Ir and 0.39 0.05 ng Ir per 106 cells, respectively;
Table S3). Uptake of 1-py by A2780 cells was concentration-
and time-dependent, rapid in the first 30 minutes, and slowly
increasing during the four-hour study (Figure S4).
Some anticancer metal complexes disturb cellular redox
homeostasis by increasing the level of oxidative stress.[10] To
assess whether redox chemistry is involved in the MoA, we
co-administered 1-py and l-buthionine sulfoximine (l-BSO)
to A2780 cells. The tripeptide glutathione (GSH, g-l-Glu-l-
Cys-Gly) is an important antioxidant in cells and a scavenger
of ROS. l-BSO, an inhibitor of g-glutamylcysteine synthetase,
is often used to deplete the level of cellular GSH. A two-fold
decrease in the IC50 value (60 3 nm) was observed upon co-
incubation of 1-py with a non-toxic dose of l-BSO (5 mm ;
Figure S5 and Table S3). These data are consistent with
a MoA for 1-py that involves redox processes, as cells are
exposed to higher levels of ROS on co-incubation with l-
BSO.
To detect changes in general oxidative stress, we deter-
mined the levels of ROS in A2780 cells that are induced by 1-
py at concentrations of one third of the IC50 value, the IC50
value, and three times the IC50 value by flow cytometry
(Figure 3). This allowed the determination of the total level of
oxidative stress (combined levels of H2O2, peroxy and
hydroxyl radicals, peroxynitrite, and NO in the FL1 channel),
whilst also monitoring superoxide production (in the FL2
channel). All flow-cytometry experiments were conducted
with a drug exposure of just one hour, during which 1-py
achieved 78% of its maximum antiproliferative activity
(Table S4). We observed a substantial increase in the total
ROS ( 1230) and superoxide ( 700) levels in cells treated
with 1-py compared to untreated cells (Figure S6). No
significant changes in the ROS level were observed with
increased concentrations of 1-py, which suggests that low
doses of 1-py (1/3 of the IC50) are sufficient to maximize ROS
generation. Similar experiments were carried out using 1-Cl
and revealed that although 1-Cl also generated ROS, the level
of superoxide induction is significantly lower than for 1-py
(Figure 3B). Therefore, the level of ROS induced by the
complexes 1-py and 1-Cl correlates with their anticancer
activity.
This appears to be the first report of an organometallic
iridium anticancer complex that is able to generate significant
ROS levels in cancer cells. The highly amplified ROS levels
that are induced by 1-py and 1-Cl are likely to play an
important role in their activity. Non-enzymatic production of
Figure 3. Induction of ROS in A2780 human ovarian cancer cells. a) Comparison of flow
cytometry dot plots: Untreated cells (negative control), cells treated with ROS-inducer
pyocyanin (1 mm, positive control), cells treated with three times the amount of the IC50
value of 1-py, and cells treated with three times the amount of the IC50 value of 1-py and
NAC (5 mm). The green channel (FL1) detects total oxidative stress, and the orange
channel (FL2) detects superoxide production. b) Comparison of the populations exposed
to different concentrations (1/3 IC50, IC50, and 3IC50) of 1-Cl or 1-py and populations
exposed to the highest concentration of each iridium complex and NAC. In all cases, the
cells were exposed to the drug for one hour at 310 K.
Angewandte
Chemie
3943Angew. Chem. Int. Ed. 2014, 53, 3941 –3946  2014 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org
superoxides by xenobiotics has previously been related to the
MoAs of organic anticancer drugs such as doxorubicin.[11]
Interestingly, we found that even in the presence of a thiol,
such as the ROS scavenger N-acetyl-l-cysteine (NAC), the
iridium complex is able to cause an increase in the level of
superoxide in A2780 cancer cells (Figure 3b; see also the
Supporting Information).
Cancer cells display a redox metabolism that is distinctly
different from that of healthy cells.[3a] Normal cells are able to
control ROS levels by balancing the generation and elimi-
nation of ROS with appropriate scavenging systems.[12] To
investigate the selectivity of 1-py in terms of the production of
ROS in cancer cells versus normal cells, we determined the
ROS level in MRC-5 fibroblasts exposed to three different
concentrations of 1-py. For cells exposed to an amount of
three times the IC50 value of 1-py, the population that showed
high total oxidative stress as well as high superoxide levels
reached only 3.6% for MRC-5 normal cells (Figure S7),
compared to 92.5% for A2780 cancer cells. Similar observa-
tions were made for doses that correspond to a third of the
IC50 value and the IC50 value itself. These results can explain
the selectivity of 1-py (the higher potency of 1-py towards
A2780 cells compared to MRC-5 fibroblasts; Figure 2a).
Therefore, interference with cellular redox homeostasis in
cancer cells appears to play a major role in the MoA of 1-py
and provides an attractive approach for cancer therapy.[3]
Next, we investigated the aqueous chemistry of 1-py and,
in particular, possible reactions that could produce ROS.
First, we studied the hydrolysis (aquation) of 1-py, as this may
provide a potential MoA and interaction with possible
biological targets. The 1H NMR data reveal that the hydrol-
ysis equilibrium was established after four hours at 310 K
(63.3% hydrolyzed, t1/2= 77.8 min; Figure S8). Aquation was
reversed when pyridine was added (Figure S8c). We previ-
ously reported that 1-Cl undergoes rapid hydrolysis; this
process reached equilibrium within minutes even at 278 K.[6c]
Thus, the introduction of pyridine significantly slows down
the hydrolysis rate, which leads to an activation time that is
more compatible with transport to biological target sites.
Given the high chloride concentration in the body, we
investigated the stability of 1-py in the presence of NaCl (104,
23, and 4 mm), mimicking the Cl concentration in blood
plasma, cell cytoplasm, and cell nucleus, respectively.[13] After
one hour, 7–18% of 1-py had reacted with chloride to give 1-
Cl (Figure S9).
Coenzyme NADH plays a key role in numerous biocat-
alyzed processes. Previously, we have shown that NADH can
donate a hydride to aqua IrIII cyclopentadienyl complexes and
induce the reduction of protons to H2 and that of quinones to
semiquinones.[14] Now, we have investigated whether reac-
tions of 1-py and 1-Cl with NADH can produce ROS and thus
provide a pathway to an oxidant MoA.
When NADH (3.5 mol equiv) was added to a 0.25 mm
solution of 1-Cl, a sharp singlet at 14.7 ppm was observed
in the 1H NMR spectrum within ten minutes; this resonance
corresponds to the IrIII hydrido complex [(h5-Cpxbiph)Ir-
(phpy)(H)] (1-H ; Figure 4a). The large upfield shift of this
peak compared to that for [(h5-Cp*)Ir(phen)(H)]+ (ca.
11.1 ppm)[14a] is notable. NADH was converted into its
oxidized form NAD+ (new peaks at 8.98, 9.35, and 9.58 ppm
assignable to the hydrogen atoms at the C4, C6, and
C2 positions of the nicotinamide ring of NAD+). These data
suggest that 1-Cl can accept a hydride from NADH. Similar
results were obtained for the reaction of NADH with 1-py
(Figure S10), but the reaction was much slower (a few hours),
perhaps because of the difference in hydrolysis rates of the
two iridium complexes. Strikingly, data from UV/Vis spec-
troscopy suggested that 1-Cl and 1-py can act as catalysts for
hydride transfer from NADHwith turnover numbers (TONs)
of 8.2 and 7.6, respectively; the concentration of reacted
NADH is calculated by measuring the absorption difference
at 339 nm (Figure 4b). Importantly, the ROS hydrogen
peroxide (H2O2) was detected by the appearance of a blue
color on an H2O2 test stick in a solution of 1-py (1 mm) with
NADH (3 mol equiv) in MeOH/H2O (3:7; Figure 4c), reveal-
ing that H2O2 was present in a concentration of approximately
0.22 mm, the level probably being limited by the solubility of
oxygen (ca. 0.23 mm at 288 K).[15] NoH2O2 was detected in the
presence of added catalase or when the reaction was carried
out under a nitrogen atmosphere.
To the best of our knowledge, hydride transfer from
NADH to O2 has not been reported previously, although
Noyori-type transfer hydrogenation catalysts, such as
[(h5-Cp*)Ir(TsDPEN)(H)] (TsDPEN=H2NCHPhCHPhN-
(SO2C6H4CH3)
), can undergo oxidative addition of O2 to
give hydroperoxide intermediates and H2O as a product in
MeCN and CH2Cl2.
[16] The production of the ROS H2O2 by
electron transfer from NADH to O2 might therefore be
involved in the activity of 1-py (and 1-Cl) in cancer cells.
Electrochemical studies ruled out the possibility that an
iridium-centered redox process is related to the ROS
production (Figure S11).
Figure 4. Reactions of 1-Cl and 1-py with NADH. a) 1H NMR spectra
of the reaction between 1-Cl (0.25 mm) and NADH (3.5 mol equiv) in
CD3OD/H2O (1:1) at 310 K. Left: low-field region; right: high-field
region showing the resonances that arise from the Cp methyl substitu-
ents; top: IrH hydride peak (4). b) UV/Vis spectra of the reaction of
NADH (87 mm) with 1-Cl (0.8 mm) in MeOH/H2O (1.6:98.4) at 310 K
for 20 h. c) Detection of hydrogen peroxide in a solution of 1-py
(1 mm) with NADH (3 mol equiv) in MeOH/H2O (3:7, v/v) at 310 K.
After 24 hours, H2O2 (ca. 0.22 mm) was detected by Quantofix
peroxide test sticks.
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GSH is abundant (at millimolar concentrations) in cells
and participates in the detoxification of many anticancer
drugs.[17] Therefore, we investigated whether the reactions of
1-py and 1-Clwith GSHmight be involved in the difference in
their anticancer activities. 1H NMR spectra showed that 95%
of 1-py had reacted with GSH after 12 hours to yield complex
[(h5-Cpxbiph)Ir(phpy)(SG)] (1-SG ; Figure S12). The four CH3
groups in the Cpxbiph ring of 1-py give rise to three singlets with
an intensity ratio of 1:1:2, but split into six peaks with an
intensity ratio of 1:1:2:1:1:2 for the glutathione adduct 1-SG
(Figure S12). Complex 1-py, which contains an unsymmetric
chelating ligand, is chiral; therefore, two diastereomeric
glutathione adducts are expected. Other 1H NMR peaks for
1-SG were assigned with the aid of a 2D NOESY spectrum
(Figure S13). The significant upfield shifts of the resonances
for Glu-g CH2, Glu-b CH2, and Cys-b CH2 of 1-SG compared
to those of free GSH are notable (Figure S12d). The
formation of 1-SG was confirmed by ESI-MS analysis (Fig-
ure S14). To the best of our knowledge, this is the first
characterization of a cyclopentadienyl iridium complex con-
taining glutathione as a ligand.
Whereas the substitution of pyridine in 1-py by GSH was
slow, the reaction of GSHwith 1-Cl proceeded rapidly to yield
1-SG (< 30 min); this difference may influence the fate of the
two complexes in cells. Indeed, decreasing the cellular level of
GSH with l-BSO (Figure S5) resulted in a larger increase in
activity for 1-Cl compared to 1-py, perhaps indicating the
higher extent of deactivation of 1-Cl by GSH compared to the
less reactive 1-py.
Our studies of the aqueous chemistry of 1-Cl and 1-py
(summarized in Figure 5) provide a molecular basis for their
anticancer activity and for their differences in potency.
Complex 1-Cl is more reactive towards hydrolysis, GSH,
and NADH than 1-py. Such a high reactivity can lead to side
reactions (deactivation) so that the amount of iridium species
that reach intracellular target sites is reduced. The relatively
unreactive complex 1-py shows enhanced accumulation in
cancer cells, which is followed by the reaction with NADH
and the generation of the ROS hydrogen peroxide. In cells,
this also appears to lead to a build-up of superoxide. The
higher level of iridium accumulation in A2780 ovarian cancer
cells after treatment with 1-py is consistent with its ability to
generate higher levels of ROS compared to 1-Cl and its higher
anticancer potency.
Herein, we have described the synthesis and character-
ization of the new organometallic IrIII anticancer complex
[(h5-Cpxbiph)Ir(phpy)(py)]+ (1-py). The presence of the
strongly bound pyridine ligand slows down reactions (such
as hydrolysis) by several orders of magnitude compared to
those of its chlorido analogue 1-Cl. The glutathione adduct 1-
SG is formed much more slowly from complex 1-py than from
1-Cl, leading to less deactivation. Complex 1-py was found to
exhibit nanomolar activity in a wide range of cancer cell lines
in the NCI-60 screen, and is therefore an order of magnitude
more potent than the anticancer drug cisplatin. In comparison
to 1-Cl, 1-py has a more promising therapeutic index towards
cancer cells compared to normal cells.
Importantly, the iridium complexes have a MoA that is
different from that of platinum drugs. Remarkably, 1-py
induces a significant increase in the level of ROS in ovarian
cancer cells within one hour and is the first reported
organometallic iridium compound to do so. As would be
expected for an oxidant drug, the activity of 1-py is
potentiated by l-BSO. Complex 1-py accumulates in cancer
cells to a greater extent than 1-Cl and generates higher levels
of ROS.
The potential use of synthetic metal complexes for
catalyzing chemical transformations in living organisms is
currently attracting much attention.[18] Our chemical studies
reveal a basis for a novel oxidant MoA of 1-py and 1-Cl, which
involves catalytic hydride transfer from the coenzyme NADH
to oxygen to produce the ROS H2O2 as a product. This new
strategy for the rational design of oxidant catalytic organo-
iridium drugs may be highly effective for treating platinum-
resistant cancers.
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